Planning Optimal First-line Treatment for Patients With Advanced RCC

Download these slides from a live webinar for the most recent data on the optimal first-line treatment options for patients with advanced RCC.
Elizabeth R. Plimack, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.32 MB
Released: June 16, 2021

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Eisai
Exelixis, Inc.
Merck Sharp & Dohme Corp.

Related Content

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director
person default Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD
Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue